type: timeline_event
On January 21, 2021, his first full day in office, President Joe Biden signed a package of ten executive orders aimed at accelerating the federal COVID-19 response, with the invocation of the Defense Production Act as its centerpiece. The DPA orders directed federal agencies to use the act's full authorities to expand production of vaccines, testing supplies, personal protective equipment, and other critical materials. Jeff Zients, appointed as White House COVID-19 Response Coordinator, was tasked with overseeing a centralized, government-directed supply chain mobilization that stood in sharp contrast to the previous administration's fragmented and voluntary approach. Biden set a goal of 100 million vaccinations in his first 100 days, a target that required not just vaccine doses but also the syringes, vials, needles, and ultra-cold storage equipment necessary to deliver them.
The DPA invocations were broad and systematic, covering vaccine manufacturing inputs such as lipid nanoparticles, bioreactor bags, and specialized filters that had become bottlenecks in production. The administration used the act's Title I priority-rating authority to ensure that vaccine manufacturers received supplies ahead of other customers, and its Title III authorities to fund expansion of domestic manufacturing capacity. The approach represented the most aggressive peacetime use of the Defense Production Act since the Korean War era, and it produced results: the 100 million vaccination goal was met weeks ahead of schedule, and by mid-2021 the United States had administered more doses per capita than most peer nations.
However, the Biden DPA invocations also revealed the limits of emergency mobilization within a profit-driven healthcare system. The federal government used billions of taxpayer dollars to subsidize production, fund manufacturing expansion, and guarantee purchase commitments for pharmaceutical companies, but it did not use the DPA's authority to require technology transfer, compulsory licensing, or price controls on the resulting vaccines. Pfizer, Moderna, and Johnson and Johnson retained full intellectual property rights over vaccines that had been developed with substantial public investment, and they used that leverage to set premium prices that generated tens of billions in profits. The administration also resisted using DPA authorities to compel vaccine manufacturers to share technology with developing nations, contributing to the global vaccine apartheid that left much of the world unvaccinated well into 2022. Biden's use of the DPA was far more effective than Trump's, but it demonstrated that even aggressive government mobilization could be structured to protect corporate profit margins rather than maximize public health outcomes.